Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 55111-196

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 55111-196). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container (Container)

Packaging label for Clopidogrel Tablets USP 75 mg, film-coated tablets. The label indicates a package count of 90 tablets and states the product is Rx only. It includes dosage and storage instructions, a QR code for the medication guide, and is labeled by Dr. Reddy's Laboratories Limited. The label also shows the product NDC as 55111-196.*

FDA Label Image

Container1

Label for Clopidogrel Tablets, USP 75 mg, a prescription oral film-coated tablet. The label indicates a package of 90 tablets. It includes instructions for pharmacists to dispense the Medication Guide to each patient. Manufactured by Dr. Reddy's Laboratories Limited, the label provides NDC 55111-196 and storage instructions to keep the product at controlled room temperature.*

FDA Label Image

Figure1 (Figure1)

A forest plot chart showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) of clopidogrel bisulfate. The chart displays mean values and 90% confidence intervals for dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, and omeprazole 80 mg, relative to a baseline of 1.0 on the x-axis scale ranging from 0.4 to 1.4.*

FDA Label Image

Figure2 (Figure2)

A cumulative event rate line graph comparing Clopidogrel (+ aspirin) with Placebo (+ aspirin) over 12 months of follow-up. The x-axis represents months of follow-up, and the y-axis shows cumulative event rate in percentage. The graph includes a p-value indicating statistical significance.*

FDA Label Image

Figure3 (Figure3)

A forest plot chart displaying hazard ratios with 95% confidence intervals for Clopidogrel versus placebo across various subgroups, including age, gender, race, cardiovascular history, diabetes, and medication use. The x-axis ranges from 0.3 to 1.4 hazard ratio, indicating the comparative effect favoring Clopidogrel or placebo.*

FDA Label Image

Figure4 (Figure4)

A Kaplan-Meier survival curve depicting the percentage of deaths before first hospital discharge over a 28-day period following randomization. Two groups are compared: placebo and clopidogrel. The graph includes annotations of death counts and proportional risk reduction between the groups.*

FDA Label Image

Figure5 (Figure5)

A line graph showing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days since randomisation. Two curves compare placebo and clopidogrel, showing lower event percentages with clopidogrel (9.2%) compared to placebo (10.1%). The graph notes a 9% proportional risk reduction with clopidogrel (p=0.002).*

FDA Label Image

Figure6 (Figure6)

A forest plot chart displaying odds ratios with 99% confidence intervals comparing Clopidogrel versus placebo across various subgroups such as gender, age, time since onset, systolic blood pressure, heart rate, and fibrinolytic agent administration. The plot illustrates the point estimates and confidence intervals for each subgroup and the overall effect, with the horizontal axis representing odds ratios ranging approximately from 0.7 to 1.3.*

FDA Label Image

Figure7 (Figure7)

A line graph comparing the cumulative event rate (%) of fatal or non-fatal vascular events over 36 months of follow-up for Clopidogrel and Aspirin. The x-axis represents months of follow-up (0 to 36), and the y-axis shows cumulative event rate from 0% to 16%. The graph shows Clopidogrel with a slightly lower event rate than Aspirin, with a reported P value of 0.045.*

FDA Label Image

Figure8 (Figure8)

A forest plot chart comparing the hazard ratios of Clopidogrel versus Aspirin across conditions: stroke, myocardial infarction (MI), peripheral artery disease (PAD), and overall. The plot includes numerical counts and percentages for both treatments and visually indicates favorability on a hazard ratio scale from 0.6 to 1.3 with confidence intervals.*

FDA Label Image

Structure (Structure)

Chemical structure of Clopidogrel bisulfate, showing its molecular arrangement including the sulfur, oxygen, chlorine atoms and associated functional groups, along with the bisulfate component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.